The purpose of this study is to investigate the treatment of metastatic pancreatic cancer. It will focus on the use of paclitaxel polymeric micelles combined with another medication as a first-line treatment.
This study evaluates the effectiveness and safety of the treatment to determine if it provides a beneficial option for patients. The focus is on assessing how well the treatment works and its safety profile.
- Who can participate: Adults aged 18 to 75 years with metastatic pancreatic cancer can participate. Key eligibility includes no prior systemic therapy for metastatic cancer and good organ function.
- Study details: Participants will receive treatment with paclitaxel polymeric micelles plus another medication. Some may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand